{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T03:41:19Z","timestamp":1784691679899,"version":"3.55.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T00:00:00Z","timestamp":1749513600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2024-00441289"],"award-info":[{"award-number":["RS-2024-00441289"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2025-00512586"],"award-info":[{"award-number":["RS-2025-00512586"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2022-NR069380"],"award-info":[{"award-number":["RS-2022-NR069380"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.biopha.2025.118245","type":"journal-article","created":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T09:33:37Z","timestamp":1750066417000},"page":"118245","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Advanced breast cancer immunotherapy: Surface modification of NK cells for embedding antibody-drug conjugates"],"prefix":"10.1016","volume":"189","author":[{"given":"Su Yeon","family":"Lim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seungmin","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihyeon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeongbeom","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong-Ann","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jina","family":"Yun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seok-Beom","family":"Yong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2930-6260","authenticated-orcid":false,"given":"Young-Wook","family":"Won","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7341-8788","authenticated-orcid":false,"given":"Kwang Suk","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2025.118245_bib1","first-page":"1469","article-title":"[Immunological aspects of anticancer chemotherapy]","volume":"192","author":"Zitvogel","year":"2008","journal-title":"Bull. Acad. Natl. Med."},{"key":"10.1016\/j.biopha.2025.118245_bib2","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/nrc1613","article-title":"Immunotherapy and chemotherapy--a practical partnership","volume":"5","author":"Lake","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.biopha.2025.118245_bib3","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1158\/2159-8290.CD-20-1680","article-title":"The next decade of immune checkpoint therapy","volume":"11","author":"Sharma","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.biopha.2025.118245_bib4","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrd3980","article-title":"Antibody-drug conjugates","volume":"12","author":"Zolot","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biopha.2025.118245_bib5","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S0140-6736(19)31774-X","article-title":"Antibody-drug conjugates for cancer","volume":"394","author":"Chau","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2025.118245_bib6","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1158\/2159-8290.CD-24-0708","article-title":"The journey of Antibody-Drug conjugates: lessons learned from 40 years of development","volume":"14","author":"Colombo","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.biopha.2025.118245_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15153886","article-title":"Antibody-Drug conjugates: a review of approved drugs and their clinical level of evidence","volume":"15","author":"Gogia","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2025.118245_bib8","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/d41573-021-00054-2","article-title":"The oncology market for antibody-drug conjugates","volume":"20","author":"do Pazo","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biopha.2025.118245_bib9","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.jconrel.2012.01.026","article-title":"Antibody-drug conjugates: basic concepts, examples and future perspectives","volume":"161","author":"Casi","year":"2012","journal-title":"J. Control Release"},{"key":"10.1016\/j.biopha.2025.118245_bib10","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41571-023-00850-2","article-title":"Exploring the next generation of antibody-drug conjugates","volume":"21","author":"Tsuchikama","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.biopha.2025.118245_bib11","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14081707","article-title":"The potential of topoisomerase Inhibitor-Based Antibody-Drug conjugates","volume":"14","author":"Han","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.biopha.2025.118245_bib12","doi-asserted-by":"crossref","first-page":"1800447","DOI":"10.1002\/advs.201800447","article-title":"One-Step method for instant generation of advanced allogeneic NK cells","volume":"5","author":"Lee","year":"2018","journal-title":"Adv. Sci."},{"key":"10.1016\/j.biopha.2025.118245_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.cej.2023.145211","article-title":"Lipid anchor-mediated NK cell surface engineering for enhanced cancer immunotherapy","volume":"473","author":"Kim","year":"2023","journal-title":"Chem. Eng. J."},{"key":"10.1016\/j.biopha.2025.118245_bib14","article-title":"Surface engineering of natural killer cells with CD44-targeting ligands for augmented cancer immunotherapy","volume":"20","author":"Kim","year":"2024","journal-title":"Small"},{"key":"10.1016\/j.biopha.2025.118245_bib15","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41573-019-0052-1","article-title":"NK cells for cancer immunotherapy","volume":"19","author":"Shimasaki","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biopha.2025.118245_bib16","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13045-020-01014-w","article-title":"NK cell-based cancer immunotherapy: from basic biology to clinical development","volume":"14","author":"Liu","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.biopha.2025.118245_bib17","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41571-020-0426-7","article-title":"Exploring the NK cell platform for cancer immunotherapy","volume":"18","author":"Myers","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.biopha.2025.118245_bib18","doi-asserted-by":"crossref","DOI":"10.3390\/ma9120994","article-title":"Fc-Binding ligands of immunoglobulin G: an overview of high affinity proteins and peptides","volume":"9","author":"Choe","year":"2016","journal-title":"Materials"},{"key":"10.1016\/j.biopha.2025.118245_bib19","first-page":"561","article-title":"Analysis and use of the Serum-Albumin-Binding domains of streptococcal Protein-G","author":"Eliasson","year":"1990","journal-title":"Genet. Transform. Expr."},{"key":"10.1016\/j.biopha.2025.118245_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioadv.2022.213059","article-title":"Lipid-mediated ex vivo cell surface engineering for augmented cellular functionalities","volume":"140","author":"Kim","year":"2022","journal-title":"Biomater. Adv."},{"key":"10.1016\/j.biopha.2025.118245_bib21","article-title":"Networked cluster formation via trigonal lipid modules for augmented ex vivo NK cell priming","volume":"25","author":"Park","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2025.118245_bib22","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40580-023-00406-1","article-title":"Tailoring tumor-recognizable hyaluronic acid-lipid conjugates to enhance anticancer efficacies of surface-engineered natural killer cells","volume":"10","author":"Lee","year":"2023","journal-title":"Nano Converg."},{"key":"10.1016\/j.biopha.2025.118245_bib23","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s40824-023-00404-8","article-title":"Polymeric biomaterial-inspired cell surface modulation for the development of novel anticancer therapeutics","volume":"27","author":"Jangid","year":"2023","journal-title":"Biomater. Res."},{"key":"10.1016\/j.biopha.2025.118245_bib24","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics16091189","article-title":"Synergistic Chemo-Immunotherapy: recombinant fusion Protein-Based surface modification of NK cell for targeted cancer treatment","volume":"16","author":"Lim","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.biopha.2025.118245_bib25","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1146\/annurev-med-062315-120245","article-title":"CAR t cell therapy for solid tumors","volume":"68","author":"Newick","year":"2017","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.biopha.2025.118245_bib26","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.1111\/cas.14993","article-title":"CAR-NK cell in cancer immunotherapy; a promising frontier","volume":"112","author":"Marofi","year":"2021","journal-title":"Cancer Sci."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225004391?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225004391?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T11:48:23Z","timestamp":1754653703000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332225004391"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":26,"alternative-id":["S0753332225004391"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118245","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advanced breast cancer immunotherapy: Surface modification of NK cells for embedding antibody-drug conjugates","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118245","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118245"}}